文献速递免疫规划卫生政策与健康促进

临床免疫安全评估(CISA)项目:COVID-19疫苗咨询与病例审查

Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews.
PubMed 文献 · Vaccine · 2025-09-27

CISA项目由CDC免疫安全办公室与七家医学研究中心组成,在COVID-19疫情期间建立24/7待命咨询服务,对79例临床病例进行综合咨询(73例为COVID-19疫苗免疫接种后不良事件,6例为接种前问题)。73例AEFI咨询中31例(42%)涉及神经系统症状,14例(19%)涉及过敏或超敏症状;24份(30%)提供者满意度调查全部认为服务有帮助;38份(48%)患者随访调查中14例(37%)报告后续COVID-19疫苗耐受良好。

要点

  • 2020年12月14日至2022年12月31日共完成79例综合临床病例咨询。
  • 73例AEFI咨询中神经系统症状31例(42%),过敏或超敏症状14例(19%)。
  • 38份患者随访调查中14例(37%)报告后续COVID-19疫苗耐受良好。

核心结论

  • 尽管满意度和患者随访调查参与率低,CISA咨询服务通过综合临床病例咨询和疫苗安全指导为HCP提供了及时的COVID-19疫苗安全评估,在疫情应对中发挥了独特作用。

研究设计与样本

  • CISA项目是由CDC免疫安全办公室与七家医学研究中心组成的疫苗安全专家网络,负责回应美国HCP的咨询并开展疫苗安全研究。
  • COVID-19疫情期间CDC建立24/7待命CISA咨询服务,对咨询进行审查并选择部分临床最复杂的病例进行综合结构化CISA临床病例咨询。
  • 保密咨询后向提供者发送满意度调查,并询问患者结局及患者是否耐受后续COVID-19疫苗接种。

主要发现

  • 2020年12月14日至2022年12月31日,CDC工作人员和CISA调查者共进行79例综合临床病例咨询,其中73例关于COVID-19疫苗AEFI,6例为接种前问题。
  • 73例AEFI咨询中31例(42%)包括神经系统症状,14例(19%)包括过敏或超敏症状,心脏病学和血液学咨询构成其余大部分。
  • 24份(30%)提供者满意度调查被返回,所有受访者均认为服务有帮助。
  • 38份(79份中48%)患者随访调查被返回,其中14例(37%)报告后续COVID-19疫苗已接种且在病例患者中耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 满意度和患者随访调查参与率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Clinical Immunization Safety Assessment (CISA) Project is a network of vaccine safety experts from the Centers for Disease Control and Prevention (CDC) Immunization Safety Office (ISO) and seven medical research centers. CISA responds to inquiries from U.S. healthcare providers (HCPs) and conducts vaccine safety research. This report summarizes the CISA approach to addressing provider vaccine safety inquiries during the COVID-19 pandemic and describes these consultations. METHODS: During the COVID-19 pandemic, CDC established a 24/7 on-call CISA consultation service. Inquiries were reviewed, and some of the most clinically complex were selected for comprehensive, structured CISA clinical case consultations. After confidential consultations, provider satisfaction surveys were sent, and providers were queried about patient outcomes and whether patients tolerated subsequent COVID-19 vaccinations. RESULTS: From December 14, 2020, through December 31, 2022, CDC staff and CISA investigators conducted 79 comprehensive clinical case consultations (73 regarding adverse events following immunization (AEFI) after COVID-19 vaccine, and 6 pre-vaccination questions). Of the 73 AEFI consultations, 31 (42 %) included neurologic and 14 (19 %) allergic or hypersensitivity symptoms. Cardiology and hematology inquiries comprised most of the remainder. Twenty-four (30 %) provider satisfaction surveys were returned; all respondents found the service helpful. Of 38 (79 total; 48 %) returned patient follow-up surveys, 14 (37 %) reported that subsequent COVID-19 vaccines were administered and were well-tolerated in case patients. DISCUSSION: Despite low participation rate in satisfaction and patient follow-up surveys, the CISA consultation service provided timely COVID-19 vaccine safety evaluations for HCPs through comprehensive clinical case consultations and vaccine safety guidance, a unique role in the pandemic response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Campbell PM, Ess GJ, Lale A, et al. Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews. Vaccine. 2025. PMID: 41016231. doi:10.1016/j.vaccine.2025.127781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。